Tezepelumab CRSwNP Real World Study (CREW Study)

Ki vehet részt

• Participant must be 18 years of age or older, at the time of signing the informed consent
• Confirmed diagnosis of CRSwNP for at least 12 months prior to routine care visit 1
• Participants who will be enrolled after index date need to have at least SNOT-22 prior (maximum of 4 weeks) to index date
• Documented SNOT-22 total score>=30, collected within the 4 weeks prior to the first tezepelumab dose (index date)
• Treated per the Japanese Handbook for the Management of Chronic Rhinosinusitis with Nasal Polyps for at least 30 days prior to routine care visit 1
• Physician decision that participant is eligible for treatment with tezepelumab according to local approved CRSwNP label and Optimal Clinical Use Guidelines
• Patients must be able and willing to read and comprehend written instructions, to collect PROs and medication intake and to sign the informed consent document

Ki nem vehet részt

• Patients who have received any biologic therapy for asthma or CRSwNP
• Known hypersensitivity to tezepelumab or any of its excipients
• Condition (acute or chronic) that, in the investigator's opinion, would limit the participant´s ability to complete questionnaires or participate in this study
• Patients who participate in an interventional clinical trial in the last 4 months
• Pregnancy or lactation period or planning pregnancy during the study period